## In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## 1-8. (cancelled)

- 9. (previously presented) A method of treating irritable bowel syndrome which comprises administering to a patient in need thereof a compound having NMDA receptor antagonist activity or a pharmaceutically acceptable sait thereof.
- 10. (withdrawn) A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound having NMDA receptor antagonist activity and a pharmaceutically acceptable carrier.
- 11. (withdrawn) The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor antagonist activity is a non-competitive NMDA receptor antagonist.

12. (withdrawn) The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor antagonist activity is a compound of formula (I) or a metabolite or isomer thereof

$$R^1$$
-CH2  $R^2$   $NH_2$   $NH_2$   $R^3$   $R^4$ 

where:

 $R^1$  and  $R^2$  are independently phenyl or 4-fluorophenyl;  $R^3$  is hydrogen,  $C_{1-6}$  alkyl or methoxycarbonyl;

R4 is hydrogen or methyl;

as a free base or a pharmaceutically acceptable salt thereof.

13. (previously presented) The method according to claim 9 wherein the compound is a non-competitive NMDA receptor antagonist.

14. (previously presented) The method according to claim 9 wherein the compound is a compound of formula (I) or a metabolite or isomer thereof

where:

 $R^1$  and  $R^2$  are independently phenyl or 4-fluorophenyl;

R3 is hydrogen, C1-6 alkyl or methoxycarbonyl;

R4 is hydrogen or methyl;

as a free base or a pharmaceutically acceptable salt thereof.

- 15. (previously presented) The method according to claim 14 wherein the compound is remacemide or a pharmaceutically acceptable salt thereof.
- 16. (previously presented) The method according to claim 14 wherein the compound is 2,3-diphenyl-2-propylamine or a pharmaceutically acceptable salt thereof.
- 17. (previously presented) The method according to claim 14 wherein the compound is (S)-1-phenyl-2-(2-pyridyl)ethanamine or a pharmaceutically acceptable salt thereof.

- 18. (previously presented) The method according to claim 9 wherein the compound is memantine or a pharmaceutically acceptable salt thereof.
- 19. (previously presented) The method according to claim 9 wherein the compound is 2-amino-N-(1,2-diphenylethyl)acetamide, alpha-phenyl-1H-pyrazole-1-ethanamine, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine, or 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine or a pharmaceutically acceptable salt thereof.